Open AccessMicrocosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi
Author(s) -
Matthew Painschab,
Racquel E. Kohler,
Edwards Kasonkanji,
Takondwa Zuze,
Bongani Kaimila,
Richard Nyasosela,
Ruth Nyirenda,
Robert Krysiak,
Satish Gopal
Publication year - 2019
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.19.00059
Subject(s) - medicine , ifosfamide , diffuse large b cell lymphoma , chop , context (archaeology) , salvage therapy , rituximab , gemcitabine , oncology , etoposide , chemotherapy , lymphoma , biology , paleontology
To describe the cost of treating diffuse large B-cell lymphoma (DLBCL) in Malawi under the following circumstances: (1) palliation only, (2) first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), (3) salvage etoposide, ifosfamide, and cisplatin (EPIC), and (4) salvage gemcitabine and oxaliplatin (GEMOX).